CTOs on the Move

Afferent Pharmaceuticals

www.afferentpharma.com

 
Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Afferent Pharmaceuticals raised $55M on 07/08/2015

Similar Companies

GlamAndGo

"Glam&Go`s mission is to make beauty convenient. Our express styling bars are located where women need them most – fitness centers, hotels, residential & corporate towers – making great hair days accessible, affordable, quick & easy. Choose between a 30-minute signature blow out, or pop in for a 15-minute express style for just the right amount of professional pampering to get you gorgeous and going. Our Glambassador Monthly Memberships offer unlimited services, access to all locations plus exclusive VIP events & gifts from our perks partners. Dubbed the “the best kept secret in hair,” our team of experienced stylists are hand-picked & extensively trained, undergoing our proprietary “Academy of Glam.” "

Health Advocate, Inc.

Health Advocate, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plymouth Meeting, PA. To find more information about Health Advocate, Inc., please visit www.healthadvocate.com

Sinochem Jiangsu Co.

Sinochem Jiangsu Co. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthLinx Executive Search

HealthLinx Executive Search is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.